Key result
Single bolus t-PA matches infusion dosing for 60-minute infarct-related vessel patency and microvascular reperfusion.
Why the study?
Does single bolus administration of t-PA provide equivalent efficacy to infusion dosing for infarct related vessel patency and microvascular perfusion in a canine model of coronary occlusion?
RCT (n=16)
Randomized
Does single bolus administration of t-PA provide equivalent efficacy to infusion dosing for infarct related vessel patency and microvascular perfusion in a canine model of coronary occlusion?
In a canine model of coronary occlusion, a single bolus of t-PA demonstrated equivalent efficacy to an infusion in achieving infarct-related vessel patency and microvascular reperfusion.
Answers are grounded in this paper and cite their sources.
Supports bolus t-PA testing in human trials; leaves open translation to clinical STEMI outcomes.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Longridge et al. (1991) conducted an RCT in Coronary arterial thrombotic occlusion (n=16). Recombinant tissue plasminogen activator (t-PA) single bolus vs. t-PA infused intravenously at 0.6 x 10(6) IU.kg-1.h-1 was evaluated on 60 minute infarct related vessel patency (IRVP). Single bolus administration of t-PA showed equivalent efficacy to infusion dosing for 60-minute infarct related vessel patency, microvascular reperfusion, and reocclusion.
Synapse has enriched 10 related papers. Consider them for comparative context: